ANL shorts rebuild fast as earnings loom

ANL heads into its November 13 earnings date with short sellers building positions at the fastest pace in months, even as the stock sits 32% below its recent peak.

Short interest has become the defining tension here. Bears added positions sharply last week, with short interest jumping 16% in seven days to 14.1% of the free float, one of the more aggressive weekly rebuilds seen in a clinical-stage biotech of this size. The move follows a 26% rise in short interest over the past month, taking the position from around 4.4 million shares to 5.2 million. Days to cover, based on the latest FINRA fortnightly figure, stands at nearly 12, meaning an unwind would take two-plus weeks of normal volume. The borrow market adds nuance. Availability has swung violently, collapsing to just 8% on October 21 before bouncing back to 76% by October 26, suggesting short sellers are working around a lending pool that can tighten fast. Cost to borrow, at 6.4%, has actually eased over the past month from above 8.5% in early October, so the marginal cost of holding a short is coming down even as the position grows. The ORTEX short score hit 83.95, its highest reading of the past two weeks and near the top of the universe by percentile rank.

The Street, however, is firmly in the other camp. All seven analysts covering ANL rate it a buy, with a consensus price target around $29.50 against a current price of $10.58. The most recent action was Jefferies initiating coverage with a buy and a $31 target in early September, joined by HC Wainwright reiterating buy at $20 and Lucid Capital assuming coverage with a $49 target. That analyst data is now around 47 days old, and targets range from $20 to $49, reflecting genuine disagreement on how to value a pre-revenue biotech. The bull case rests on AN9025, the company's pan-RAS(ON) inhibitor targeting metastatic pancreatic ductal adenocarcinoma. Preclinical data shows it requires 1/250th the dose of a key comparator to achieve similar efficacy. Bears point to the lack of clinical validation, the systemic toxicity risk from pan-RAS inhibition, and an estimated two-year lag behind the leading competitor in first-line mPDAC. The company carries no product revenue and rising trial costs.

Retail attention is running unusually hot. The ORTEX alt data layer, pulling from Wikipedia pageviews and ORTEX stock page traffic, shows a z-score of 4.27 for ANL's retail attention relative to its own 90-day history. That is a high reading. It does not predict a price direction, but it does suggest the stock is drawing outsized interest from non-institutional traders, which tends to amplify volatility around binary events.

Institutional positioning shows a cluster of specialist healthcare funds building exposure in the most recent quarter. Cormorant Asset Management added over 1 million shares in the June quarter to reach 6.2% of shares outstanding. Balyasny added 2.2 million shares, a new position. Point72 and Perceptive Advisors both opened fresh positions in the same period. Against that, the insider picture is more cautious. Director Ji Ping sold roughly 10,200 shares in late September at prices between $15.77 and $16.63, all open-market sales without a disclosed 10b5-1 plan. The CFO made similar-sized sales in August. None of the values are large in absolute dollar terms, around $80,000 per transaction, but the pattern is consistent selling from the mid-teens, well above the current $10.58 price.

Earnings history offers a limited but instructive backdrop. The two most recent prints produced a 3.7% and a 1.8% next-day move. The April 2026 print delivered a 17.2% five-day loss. The stock is already down 32% over the past month, so the market has been re-pricing ahead of November 13.

What to watch next: whether short interest continues to build through the earnings date, and whether the borrow availability stays loose enough to sustain the position size, or tightens again toward the sub-10% levels seen briefly last week.